Compare XRX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRX | STTK |
|---|---|---|
| Founded | 1906 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.6M | 275.9M |
| IPO Year | N/A | 2020 |
| Metric | XRX | STTK |
|---|---|---|
| Price | $2.11 | $4.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $2.50 | ★ $6.20 |
| AVG Volume (30 Days) | ★ 3.9M | 810.6K |
| Earning Date | 01-29-2026 | 03-26-2026 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,022,000,000.00 | $1,000,000.00 |
| Revenue This Year | $11.12 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.88 | N/A |
| 52 Week Low | $1.44 | $0.69 |
| 52 Week High | $8.56 | $4.89 |
| Indicator | XRX | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 43.76 | 51.37 |
| Support Level | $2.06 | $3.52 |
| Resistance Level | $2.34 | $4.10 |
| Average True Range (ATR) | 0.18 | 0.32 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 23.33 | 39.82 |
Xerox Holdings Corp is an original equipment manufacturing and software company. Xerox operates in one segment--design, development, and sale of printing technology and related solutions--while deriving 60% of its revenue from the U.S. and 40% from international markets. The company is an OEM of multifunction printers, or MFPs (printers that can print, copy, and scan), focusing on large enterprise markets. Apart from equipment, the company provides post-sales services like managed print services help to bring smart servicing and efficiencies to how employers use their print/copy equipment. Xerox is attempting to enter new markets like digital print packaging solutions and printed electronics.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.